Efficacy of anti-IL-2 receptor antibodies compared to no induction and to antilymphocyte antibodies in renal transplantation

American Journal of Transplantation

Volumn 7, Issue 7, 2007, Pages 1832-1842

  Patlolla, V ^a   Zhong, X ^a   Reed, G W ^a   Mandelbrot, D A ^a,b  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Anti IL 2 alpha chain receptor antibody; Anti lymphocyte antibodies; Basiliximab; Daclizumab; Immunosuppression; Renal transplantation

Indexed keywords

BASILIXIMAB; DACLIZUMAB; INTERLEUKIN 2 RECEPTOR ANTIBODY; LYMPHOCYTE ANTIBODY; OKT 3; THYMOCYTE ANTIBODY;

ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; GRAFT FAILURE; GRAFT REJECTION; GRAFT SURVIVAL; HLA MATCHING; HUMAN; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK;

EID: 34250158081     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2007.01860.x     Document Type: Article

References (28)

1. Nashan B, Moore R, Amlot P, Schmidt AG, Abeywickrama K, Soulillou JP. Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study Group. Lancet 1997 350 : 1193 1198.
2. Vincenti F, Kirkman R, Light S et al. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group. N Engl J Med 1998 338 : 161 165.
3. Kahan BD, Rajagopalan PR, Hall M. Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonal antibody. United States Simulect Renal Study Group. Transplantation 1999 67 : 276 284.
4. Nashan B, Light S, Hardie IR, Lin A, Johnson JR. Reduction of acute renal allograft rejection by daclizumab. Daclizumab Double Therapy Study Group. Transplantation 1999 67 : 110 115.
5. Ponticelli C, Yussim A, Cambi V et al. A randomized, double-blind trial of basiliximab immunoprophylaxis plus triple therapy in kidney transplant recipients. Transplantation 2001 72 : 1261 1267.
6. Lawen JG, Davies EA, Mourad G et al. Randomized double-blind study of immunoprophylaxis with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in combination with mycophenolate mofetil-containing triple therapy in renal transplantation. Transplantation 2003 75 : 37 43.
7. Sheashaa HA, Bakr MA, Ismail AM, Sobh MA, Ghoneim MA. Basiliximab reduces the incidence of acute cellular rejection in live-related-donor kidney transplantation: A three-year prospective randomized trial. J Nephrol 2003 16 : 393 398.
8. Ahsan N, Holman MJ, Jarowenko MV, Razzaque MS, Yang HC. Limited dose monoclonal IL-2R antibody induction protocol after primary kidney transplantation. Am J Transplant 2002 2 : 568 573.
9. Folkmane I, Bicans J, Amerika D, Chapenko S, Murovska M, Rosentals R. Low rate of acute rejection and cytomegalovirus infection in kidney transplant recipients with basiliximab. Transplant Proc 2001 33 : 3209 3210.
10. Webster AC, Playford EG, Higgins G, Chapman JR, Craig JC. Interleukin 2 receptor antagonists for renal transplant recipients: A meta-analysis of randomized trials. Transplantation 2004 77 : 166 176.
11. Adu D, Cockwell P, Ives NJ, Shaw J, Wheatley K. Interleukin-2 receptor monoclonal antibodies in renal transplantation: Meta-analysis of randomised trials. BMJ 2003 326 : 789.
12. Cherikh WS, Kauffman HM, McBride MA, Maghirang J, Swinnen LJ, Hanto DW. Association of the type of induction immunosuppression with posttransplant lymphoproliferative disorder, graft survival, and patient survival after primary kidney transplantation. Transplantation 2003 76 : 1289 1293.
13. Sollinger H, Kaplan B, Pescovitz MD et al. Basiliximab versus antithymocyte globulin for prevention of acute renal allograft rejection. Transplantation 2001 72 : 1915 1919.
14. Mourad G, Rostaing L, Legendre C, Garrigue V, Thervet E, Durand D. Sequential protocols using basiliximab versus antithymocyte globulins in renal-transplant patients receiving mycophenolate mofetil and steroids. Transplantation 2004 78 : 584 590.
15. Lebranchu Y, Bridoux F, Buchler M et al. Immunoprophylaxis with basiliximab compared with antithymocyte globulin in renal transplant patients receiving MMF-containing triple therapy. Am J Transplant 2002 2 : 48 56.
16. Soulillou JP, Cantarovich D, Le Mauff B et al. Randomized controlled trial of a monoclonal antibody against the interleukin-2 receptor (33B3.1) as compared with rabbit antithymocyte globulin for prophylaxis against rejection of renal allografts. N Engl J Med 1990 322 : 1175 1182.
17. Haririan A, Morawski K, Sillix DH et al. Induction therapy with basiliximab versus Thymoglobulin in African-American kidney transplant recipients. Transplantation 2005 79 : 716 721.
18. Nampoory MR, Abdulhalim M, Johny KV et al. Bolus anti-thymocyte globulin induction in renal transplant recipients: A comparison with conventional ATG or anti-interleukin-2 receptor antibody induction. Transplant Proc 2002 34 : 2916 2919.
19. Tullius SG, Pratschke J, Strobelt V et al. ATG versus basiliximab induction therapy in renal allograft recipients receiving a dual immunosuppressive regimen: One-year results. Transplant Proc 2003 35 : 2100 2101.
20. Brennan DC, Daller JA, Lake KD, Cibrik D, Del Castillo D, Thymoglobulin Induction Study Group. Rabbit antithymocyte globulin versus basiliximab in renal transplantation. N Engl J Med 2006 355 : 1967 1977.
21. Knight RJ, Kerman RH, Schoenberg L et al. The selective use of basiliximab versus thymoglobulin in combination with sirolimus for cadaveric renal transplant recipients at low risk versus high risk for delayed graft function. Transplantation 2004 78 : 904 910.
22. U.S. Department of Health and Human Services. 2005 Annual Report of the U.S. Organ Procurement and Transplantation Network and the Scientific Registry of Transplant Recipients: Transplant Data 1995-2004. Rockville, MD : Health Resources and Services Administration, Healthcare Systems Bureau, Division of Transplantation.
23. Sho M, Yamada A, Najafian N et al. Physiological mechanisms of regulating alloimmunity: Cytokines, CTLA-4, CD25+ cells, and the alloreactive T cell clone size. J Immunol 2002 169 : 3744 3751.
24. Brennan DC. Thymoglobulin versus simulect for induction immunosuppression in cadaveric renal transplant recipients: Expanded results from a prospective, randomized, multicenter trial. American Journal of Transplantation: Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2003 3 : 438 439.
25. Meier-Kriesche HU, Steffen BJ, Chu AH et al. Sirolimus with neoral versus mycophenolate mofetil with neoral is associated with decreased renal allograft survival. Am J Transplant 2004 4 : 2058 2066.
26. Lohr J, Knoechel B, Abbas AK. Regulatory T cells in the periphery. Immunol Rev 2006 212 : 149 162.
27. Fehervari Z, Yamaguchi T, Sakaguchi S. The dichotomous role of IL-2: Tolerance versus immunity. Trends Immunol 2006 27 : 109 111.
28. Opelz G, Dohler B. Lymphomas after solid organ transplantation: A collaborative transplant study report. Am J Transplant 2004 4 : 222 230.